Alliance Pharma PLC Changes to interests of a significant shareholder (5070I)
June 19 2017 - 10:16AM
UK Regulatory
TIDMAPH
RNS Number : 5070I
Alliance Pharma PLC
19 June 2017
For immediate release 19 June 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, has received a notification of a change in the interests
of a significant shareholder. In accordance with AIM rule 17, the
following details are now notified:
(a) Identity of the significant shareholder: Mr Nigel Wray
(b) Date of disclosure: 16 June 2017
(c) Date of relevant change: 15 June 2017
(d) Price, amount and class: 2,000,000 ordinary shares of 1p
each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 1.59% (direct) and 3.28% (indirect)
= 4.87% total
In compliance with DTR5, a copy of the notification received
from this investor is appended.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
------------------------------------------------------------------------------------------------
1. Identity of the issuer or ALLIANCE PHARMA PLC
the underlying issuer
of existing shares to which
voting rights are
attached:
------------------------------------------------------------- ---------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
----------------------------------------------------------------- -----------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------------- -----------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------- -----------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------- -----------------------------
Other (please
specify):
------------------------------------------------------------ --- -----------------------------
3. Full name of person(s) NIGEL WRAY
subject to the
notification obligation:
------------------------------------------------------------- ---------------------------------
4. Full name of shareholder(s) UBS PRIVATE BANKING NOMINEES
(if different from 3.): LTD
ROY NOMINEES LIMITED
------------------------------------------------------------- ---------------------------------
5. Date of the transaction 15 June 2017
and date on
which the threshold is
crossed or
reached:
------------------------------------------------------------- ---------------------------------
6. Date on which issuer 16 June 2017
notified:
------------------------------------------------------------- ---------------------------------
7. Threshold(s) that is/are
crossed or
reached: 4%
------------------------------------------------------------- ---------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- --------------------------------- --------------------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights
Shares Voting shares rights
Rights
------------- --------------- ---------------- -------------- ------------------------- -------------------------
Direct Direct Indirect Direct Indirect
------------- ----------- ------------ -------------- ------------ ----------- ------------ -----------
Ordinary
shares
GB0031030819 25,092,593 25,092,593 7,551,269 7,551,269 15,541,324 1.59% 3.28%
--------------- ---------------- -------------- ------------ ----------- ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- -------------------------------- --------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
--------------- ------------- -------------- ---------------- --------------------------- -----------------------
Nominal Delta
--------------- ------------- -------------- ---------------- --------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------
23,092,593 4.87%
-------------------------------------------------- ------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
---------------------------------------------------------------------------------------
Nigel William Wray has a beneficial interest in shares
in Alliance Pharma Plc held by the following nominees
7,551,269 held by UBS Private Banking Nominees Ltd
The family of Nigel Wray maintains a beneficial interest
in the shares held by Roy Nominees Limited - 15,541,324
Proxy Voting:
---------------------------------------------------------------------------------------
10. Name of the proxy holder: N/A
------------------------------------------------------- ------------------------------
11. Number of voting rights proxy N/A
holder will cease
to hold:
------------------------------------------------------- ------------------------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
------------------------------------------------------- ------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
473,961,681
------------------------------------------------------- ------------------------------
14. Contact name: Nigel Wray
------------------------------------------------------- ------------------------------
15. Contact telephone number: 020 7647 7647
------------------------------------------------------- ------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLGGUGGQUPMGCB
(END) Dow Jones Newswires
June 19, 2017 10:16 ET (14:16 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
